Breast Cancer Subtype as a Predictor of Lymph Node Metastasis according to the SEER Registry

Malcolm D. Mattes; Jay K. Bhatia; Daniel Metzger; Hani Ashamalla; Evangelia Katsoulakis

추천

검색

자료유형: 학술저널

저자정보: Malcolm D. Mattes (West Virginia University) Jay K. Bhatia (New York Methodist Hospital) Daniel Metzger (New York Methodist Hospital) Hani Ashamalla (New York Methodist Hospital) Evangelia Katsoulakis (New York Methodist Hospital)

저널정보: 한국유방암학회 Journal of Breast Cancer Journal of Breast Cancer Vol.18 No.2

발행연도: 2015.1

수록면: 143 - 148 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: Breast cancer subtype correlates with response to systemic therapy and overall survival (OS), but its impact on lymphatic spread is incompletely understood. In this study, we used the Surveillance, Epidemiology, and End Results registry to assess whether the subtype can predict the presence of nodal metastasis or advanced nodal stage in breast cancer. Methods: A total of 7,274 eligible patients diagnosed with T1-3 infiltrating ductal carcinoma with known estrogen or progesterone hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status, who underwent surgical excision of the primary tumor and pathologic lymph node evaluation, were included in this analysis. Patients were categorized into four breast cancer subtypes: HR+/HER2−; HR+/HER2+; HR−/HER2+; and HR−/HER2−. Binary logistic regression analysis was used to determine whether breast cancer subtype, tumor size, tumor grade, patient race, and patient age at diagnosis are independently predictive of lymph node positivity or advanced nodal stage. The Pearson chi-square test was used to determine whether progesterone receptor (PR) status had an impact on the incidence of lymph node positivity in estrogen receptor (ER) positive patients. Results: Independent predictors of nodal positivity included breast cancer subtype (p=0.040), tumor size (p<0.001), tumor grade (p<0.001), and patient age (p<0.001), whereas only tumor size (p<0.001), grade (p=0.001), and patient age (p=0.005) predicted advanced nodal stage. Triple-negative cancers had a significantly lower risk of nodal positivity than the HR+/HER2− subtype (odds ratio, 0.686; p=0.004), but no other significant differences between subtypes were observed. There was also no difference in lymph node positivity between PR+ and PR− tumors amongst ER+/HER2− (p=0.228) or ER+/HER2+ tumors (p=0.713). Conclusion: The HR+/HER2− breast cancer subtype has a higher rate of lymph node involvement at diagnosis than the triple-negative subtype. These findings may play a role in guiding regional management considerations if confirmed in further studies.

참고문헌 (29)

참고문헌 신청

Perou CM / 2000 / Molecular portraits of human breast tumours / Nature 406:747~752

Sotiriou C / 2003 / Breast cancer classification and prognosis based on gene expression profiles from a population-based study / Proc Natl Acad Sci U S A 100:10393~10398

Sørlie T / 2001 / Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications / Proc Natl Acad Sci U S A 98:10869~10874

Brenton JD / 2005 / Molecular classification and molecular forecasting of breast cancer: ready for clinical application? / J Clin Oncol 23:7350~7360

Rouzier R / 2005 / Breast cancer molecular subtypes respond differently to preoperative chemotherapy / Clin Cancer Res 11:5678~5685

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!